Results 181 to 190 of about 1,434,677 (298)

Cancer in Systemic Sclerosis: Clinical Associations and Prognostic Impact From the EUSTAR Registry

Arthritis &Rheumatology, EarlyView.
Objective Cancer represents a major cause of death in systemic sclerosis (SSc). Established risk factors are limited to specific subsets, particularly early diffuse anti‐RNA polymerase III (POLR3)–positive disease, needing further exploration. Methods We performed a nested case‐control study within the European Scleroderma Trials and Research group ...
Antonio Tonutti, Francesca Motta, Liala Moschetti, Cosimo Bruni, Carina Mihai, Claudia Iannone, Maria Rosa Pellico, Stefano Stano, Stefano Erba, Claudia Barison, Eleonora Pazzi, Andrea Benini, Beatrice Moccaldi, Kurszán Jász Dávid, Ágnes Ágoston‐Szabó, Beatrice Gabrielli, Francesca Nava, Dóra Tari, Francesca Romana Di Ciommo, Yuri Sasaki, Gonçalo Boleto, Radim Bečvář, Alejandro Brigante, Britta Maurer, Massimiliano Limonta, Rahma A. Elziaty, Fabiola Atzeni, Lilian Maria López Núñez, Roberta Foti, Francesco Benvenuti, Brigitte Granel, Elena Rezus, Leila Caillault, Sophie Blaise, Cristiana Sieiro Santos, Fabio Cacciapaglia, Roberto Giacomelli, Rossella De Angelis, Serena Guiducci, Duygu Temiz Karadag, Gabriella Szűcs, Luca Idolazzi, Gábor Kumánovics, Florenzo Iannone, Maurizio Cutolo, Gianluca Moroncini, Valeria Riccieri, Nicoletta Del Papa, Elisabetta Zanatta, Oliver Distler, Masataka Kuwana, Carlo Selmi, Maria De Santis   +52 more
wiley   +1 more source

Role of Interleukin 34 in Pulmonary Vascular Remodeling Associated With Fibrosing Interstitial Lung Disease. [PDF]

Pulm Circ
Yokokawa T, Ueda S, Nishiura K, Okochi S, Ogawara R, Kiko T, Miura S, Misaka T, Oikawa M, Masuishi Y, Kakamu T, Tanino Y, Shibata Y, Hashimoto Y, Muto S, Suzuki H, Inoue KI, Ikeda K, Nakazato K, Ishida T, Takeishi Y.   +20 more
europepmc   +1 more source

Expert Perspectives: Toward Treat‐to‐Target Management in Adult Idiopathic Inflammatory Myopathies

Arthritis &Rheumatology, EarlyView.
Treat‐to‐target has transformed the management of several rheumatic diseases through predefined therapeutic goals, structured disease assessment, and timely treatment adjustment. Despite major advances in the understanding and treatment of idiopathic inflammatory myopathies (IIM), a formal treat‐to‐target framework for adult IIM has not yet been ...
Shiri Keret, Nantakarn Pongtarakulpanit, Rohit Aggarwal   +2 more
wiley   +1 more source

Pulmonary arterial hypertension-associated cerebellar impairment extends evidence linking cardiometabolic and neurodegenerative diseases. [PDF]

J Clin Invest
Schwartz MW, Bornfeldt KE.
europepmc   +1 more source

Higher risk of Long COVID among patients with autoimmune rheumatic diseases and immunomodulatory therapy: a retrospective cohort analysis of national US data.

Arthritis &Rheumatology, Accepted Article.
Background Little is known about the prevalence of and factors associated with Long COVID in patients with autoimmune rheumatic diseases (AIRDs). Methods We conducted a retrospective cohort study using data from the National Clinical Cohort Collaborative (N3C).
Namrata Singh, A. Jerrod Anzalone, Holland Stevenson, Londyn Robinson, Lesley E. Jackson, Sandra E. Safo, Zachary Butzin‐Dozier, Kaleb Michaud, Maria I. Danila, Jasvinder A. Singh, Rena C. Patel, on behalf of the National Clinical Cohort Collaborative (N3C) Consortium   +11 more
wiley   +1 more source

Initial treatment strategies and outcomes across haemodynamic thresholds and risk stratification in incident systemic sclerosis–associated pulmonary arterial hypertension: a EUSTAR analysis

Arthritis &Rheumatology, Accepted Article.
Objective Real‐world initial treatment strategies in SSc‐PAH remain incompletely described. We aimed to characterise these strategies across haemodynamic thresholds and risk strata and evaluate outcome associations. Methods We analysed treatment‐naïve SSc‐PAH patients in EUSTAR (2000–2021) fulfilling the 2022 haemodynamic definition.
Hilde Jenssen Bjørkekjær, Cosimo Bruni, Kaspar Broch, Cathrine Brunborg, Patricia E Carreira, Paolo Airò, Carmen Pilar Simeón‐Aznar, Marie‐Elise Truchetet, Alessandro Giollo, Alexandra Balbir‐Gurman, Mickael Martin, Christopher P Denton, Armando Gabrielli, Francesco Del Galdo, Madelon C. Vonk, Håvard Fretheim, Helle Bitter, Øyvind Midtvedt, Arne K. Andreassen, Sverre Høie, Yoshiya Tanaka, Gabriela Riemekasten, Ulf Müller‐Ladner, Marco Matucci‐Cerinic, Ivan Castellví, Elise Siegert, Eric Hachulla, Øyvind Molberg, Oliver Distler, Anna‐Maria Hoffmann‐Vold, on behalf of the EUSTAR collaborators   +30 more
wiley   +1 more source

Case Report: Upfront sotatercept-based triple therapy in high-risk systemic sclerosis-associated pulmonary arterial hypertension. [PDF]

Front Cardiovasc Med
Tamura Y, Isobe S, Fujii H, Shirai Y, Kuwana M.   +4 more
europepmc   +1 more source

Sema4A neutralization reduces fibrosis and inflammation in a mouse model of systemic sclerosis and a 3D model of immunity‐driven fibrosis

Arthritis &Rheumatology, Accepted Article.
Objective We previously showed that Semaphorin4A (Sema4A) is elevated in patients with systemic sclerosis (SSc) and promotes inflammation and fibrosis in vitro. Here, we examined the effect of Sema4A neutralization in vivo and in 3D fibrosis models. Methods Sema4A plasma levels were measured by ELISA in healthy controls (n=31) and patients with SSc (n=
Jaime Marty, Sara Martinez‐Ramos, Carlos Rafael‐Vidal, Beatriz Malvar‐Fernández, Tiago Carvalheiro, Ralph G. Tieland, Ines Ramos, Wiola Marut, Ana Pinheiro‐Lopes, Ana Argibay, Brenda Maure, Caritina Vázquez‐Triñanes, Nair Pérez Gómez, David Fernández‐Fernández, Sandra Vila, Coral Mouriño, Rogier M Thurlings, Arjan van Caam, Alberto Rivera, José María Pego‐Reigosa, Timothy R. Radstake, Samuel Garcia   +21 more
wiley   +1 more source

Complete transcatheter closure of residual aortopulmonary window in an elderly patient allowing optimization of refractory pulmonary arterial hypertension therapy. [PDF]

Eur Heart J Case Rep
Akazawa Y, Higaki T, Yamaguchi O.
europepmc   +1 more source

Pentoxifylline dose finding trial in preterm neonates with suspected late onset sepsis (PTX‐trial)

British Journal of Clinical Pharmacology, EarlyView.
Aim The aim of this study (PTX‐trial) is to determine the optimal dose of pentoxifylline (PTX) in preterm neonates (gestational age < 30 weeks) with (suspected) late onset sepsis (LONS). Methods The PTX‐trial is a prospective multicentre open‐label sequential dose‐optimization study with an adapted continual reassessment method.
Serife Kurul, H. Rob Taal, Jan Mazela, Ryszard Lauterbach, Irwin K. M. Reiss, Karel Allegaert, Robert B. Flint, Sinno H. P. Simons   +7 more
wiley   +1 more source